Revenue Breakdown
Composition ()
No data
Revenue Streams
Soligenix Inc (SNGX) generates its revenue primarily from Specialized BioTherapeutics, which accounts for 100.0% of total sales, equivalent to $2.34K. Understanding this concentration is critical for investors evaluating how SNGX navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Soligenix Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -165.10%, provide a clear picture of how effectively SNGX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, SNGX competes directly with industry leaders such as KAPA and GTBP. With a market capitalization of $11.80M, it holds a significant position in the sector. When comparing efficiency, SNGX's gross margin of N/A stands against KAPA's N/A and GTBP's N/A. Such benchmarking helps identify whether Soligenix Inc is trading at a premium or discount relative to its financial performance.
